ATE402958T1 - Antagonisten des ige-rezeptors - Google Patents
Antagonisten des ige-rezeptorsInfo
- Publication number
- ATE402958T1 ATE402958T1 AT01983090T AT01983090T ATE402958T1 AT E402958 T1 ATE402958 T1 AT E402958T1 AT 01983090 T AT01983090 T AT 01983090T AT 01983090 T AT01983090 T AT 01983090T AT E402958 T1 ATE402958 T1 AT E402958T1
- Authority
- AT
- Austria
- Prior art keywords
- novel compounds
- provides
- ige
- antagonists
- ige receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/686—Anti-idiotype
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23535300P | 2000-09-26 | 2000-09-26 | |
| US27854001P | 2001-03-23 | 2001-03-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE402958T1 true ATE402958T1 (de) | 2008-08-15 |
Family
ID=26928828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01983090T ATE402958T1 (de) | 2000-09-26 | 2001-09-26 | Antagonisten des ige-rezeptors |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7101851B2 (de) |
| EP (1) | EP1366078B1 (de) |
| JP (1) | JP2004517816A (de) |
| KR (1) | KR20030036835A (de) |
| AT (1) | ATE402958T1 (de) |
| AU (2) | AU1454502A (de) |
| CA (1) | CA2420475A1 (de) |
| DE (1) | DE60135158D1 (de) |
| IL (1) | IL154522A0 (de) |
| NZ (1) | NZ524329A (de) |
| WO (1) | WO2002026781A2 (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1497654A4 (de) | 2001-08-13 | 2006-06-07 | Chen Swey Shen Alex | Immunoglobulin-e-vakzine und verwendungsverfahren dafür |
| US20030157555A1 (en) * | 2002-01-14 | 2003-08-21 | Lipps Binie V. | Diagnosis and treatment for immunoglobulin E ( IgE) implicated disorders |
| US20080081788A1 (en) * | 2002-01-14 | 2008-04-03 | Lipps Binie V | Diagnosis and treatment for immunoglobulin E (IgE) implicated disorders |
| WO2003083098A2 (de) * | 2002-03-28 | 2003-10-09 | Biomay Produktions- Und Handels-Aktiengesellschaft | Nucleinsäuresequenz und protein sowie polypeptide kodierend für mannit-dehydrogenasen oder deren teile sowie deren herstellung und verwendung in diagnostik und therapie |
| EP1714976B1 (de) * | 2004-01-05 | 2011-07-13 | Wenyan Wu | Aminosäuresequenzen des aktiven prinzips von moschus und deren essigsäuresalz sowie die herstellung und verwendung |
| WO2008028068A2 (en) * | 2006-08-30 | 2008-03-06 | Genentech, Inc. | NON-HUMAN PRIMATE FCεR1α POLYPEPTIDES |
| US8236323B2 (en) * | 2007-02-14 | 2012-08-07 | S-Cell Biosciences, Inc. | Method to treat inflammation |
| US7906149B2 (en) * | 2007-05-25 | 2011-03-15 | Boval Company, L.P. | Method for treating allergic dermatitis |
| SI2575846T1 (sl) * | 2010-05-27 | 2015-09-30 | Janssen Biotech, Inc. | Peptidi, ki vežejo receptor za inzulinu podoben rastni faktor 1 |
| WO2013020132A1 (en) * | 2011-08-04 | 2013-02-07 | The Brigham And Women's Hospital, Inc. | Methods of treating cardiovascular and metabolic diseases |
| AU2019205743B2 (en) * | 2018-01-08 | 2023-11-16 | Gi Innovation, Inc. | Extracellular domain of alpha subunit of IgE Fc receptor, pharmaceutical composition comprising same and method for producing same |
| CN111304091A (zh) * | 2019-11-28 | 2020-06-19 | 昆明理工大学 | 一种提高灵芝细胞培养中灵芝酸含量的方法 |
| WO2022192625A1 (en) | 2021-03-11 | 2022-09-15 | IgGenix, Inc. | Methods and systems for predicting allergic response |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT88641B (pt) | 1987-10-02 | 1993-04-30 | Genentech Inc | Metodo para a preparacao de uma variante de adesao |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| US5627263A (en) | 1993-11-24 | 1997-05-06 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
| US5962634A (en) * | 1994-07-08 | 1999-10-05 | Thomas Jefferson University | IgE antagonists |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| GB9715387D0 (en) * | 1997-07-23 | 1997-09-24 | Gould Hannah J | Immunoglobulin-binding polypeptides and their use |
-
2001
- 2001-09-26 KR KR10-2003-7004312A patent/KR20030036835A/ko not_active Ceased
- 2001-09-26 WO PCT/US2001/030289 patent/WO2002026781A2/en not_active Ceased
- 2001-09-26 AU AU1454502A patent/AU1454502A/xx active Pending
- 2001-09-26 US US10/381,112 patent/US7101851B2/en not_active Expired - Fee Related
- 2001-09-26 AU AU2002214545A patent/AU2002214545B2/en not_active Ceased
- 2001-09-26 JP JP2002531164A patent/JP2004517816A/ja active Pending
- 2001-09-26 EP EP01983090A patent/EP1366078B1/de not_active Expired - Lifetime
- 2001-09-26 AT AT01983090T patent/ATE402958T1/de not_active IP Right Cessation
- 2001-09-26 NZ NZ524329A patent/NZ524329A/xx unknown
- 2001-09-26 IL IL15452201A patent/IL154522A0/xx unknown
- 2001-09-26 CA CA002420475A patent/CA2420475A1/en not_active Abandoned
- 2001-09-26 DE DE60135158T patent/DE60135158D1/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2420475A1 (en) | 2002-04-04 |
| AU1454502A (en) | 2002-04-08 |
| US7101851B2 (en) | 2006-09-05 |
| NZ524329A (en) | 2008-04-30 |
| KR20030036835A (ko) | 2003-05-09 |
| JP2004517816A (ja) | 2004-06-17 |
| WO2002026781A2 (en) | 2002-04-04 |
| DE60135158D1 (de) | 2008-09-11 |
| US20040086942A1 (en) | 2004-05-06 |
| EP1366078B1 (de) | 2008-07-30 |
| IL154522A0 (en) | 2003-09-17 |
| WO2002026781A9 (en) | 2003-05-15 |
| EP1366078A2 (de) | 2003-12-03 |
| AU2002214545B2 (en) | 2008-04-03 |
| WO2002026781A3 (en) | 2003-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60028970D1 (de) | An her2 bindende peptidverbindungen | |
| BG66084B1 (bg) | Циклопентаноиндоли, състави,съдържащи такива съединения и използването им | |
| ATE451376T1 (de) | Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen | |
| EA200300441A1 (ru) | Ассоциация антагониста рецептора св1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения | |
| TW200510416A (en) | P38 inhibitors and methods of use thereof | |
| MXPA03005493A (es) | Derivados de bencimidazol y piridilmidazol como ligandos para receptores gaba. | |
| EA200500169A1 (ru) | Замещенные производные 1,3-дифенилпроп-2-ен-1-она, получение и применение | |
| EA200602062A1 (ru) | Амидосоединения и их применение в качестве фармацевтических средств | |
| CY1110965T1 (el) | Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου | |
| BR0008688A (pt) | Antagonistas de il-18 recombinantes utilizáveis no tratamento de distúrbios mediados por il-18 | |
| ATE433973T1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
| ATE409181T1 (de) | Proteomimetische verbindungen und verfahren | |
| JO2355B1 (en) | Hereditary calcitonin polypeptide receptor antagonists | |
| MXPA05005223A (es) | Diaminotriazoles utiles como inhibidores de proteinas cinasas. | |
| ATE496884T1 (de) | Sulphonylaminoessigsaeure derivate und deren verwendung als orexin rezeptor antagoniste | |
| ATE461178T1 (de) | Pyridazinyl-piperazine und deren verwendung als histamin-h3-rezeptorliganden | |
| ATE335748T1 (de) | Thienopyrimidindione und deren verwendung bei der modulierung von autoimmunerkrankungen | |
| MXPA06003363A (es) | Derivados de fenil-piperazina como moduladores de receptores muscarinicos. | |
| EP1423137A4 (de) | Lipopeptid-stereoisomere, verfahren zu ihrer herstellung und nützliche zwischenprodukte | |
| ATE479655T1 (de) | Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative | |
| DE60135158D1 (de) | Antagonisten des ige-rezeptors | |
| ATE389651T1 (de) | Als inhibitoren von c-met geeignete pyrrolzusammensetzungen | |
| EA200601217A1 (ru) | Новые конденсированные пирролокарбазолы | |
| NO20063193L (no) | Fusjonerte pyrrolokarbazoler og fremgangsmater for fremstilling derav | |
| BR0207528A (pt) | Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |